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Abstract: Background: Epithelial ovarian cancer has a poor prognosis, mostly due to its late 
diagnosis and the development of drug resistance after a first platinum-based regimen. The presence 
of a specific population of “cancer stem cells” could be responsible of the relapse of the tumor and 
the development of resistance to therapy. For this reason, it would be important to specifically target 
this subpopulation of tumor cells in order to increase the response to therapy.  
Method: We screened a chemical compound library assembled during the COST CM1106 action to 
search for compound classes active in targeting ovarian stem cells. We here report the results of the 
high-throughput screening assay in two ovarian cancer stem cells and the differentiated cells derived 
from them. 
Results and Conclusion: Interestingly, there were compounds active only on stem cells, only on 
differentiated cells, and compounds active on both cell populations. Even if these data need to be 
validated in ad hoc dose response cytotoxic experiments, the ongoing analysis of the compound 
structures will open up to mechanistic drug studies to select compounds able to improve the 
prognosis of ovarian cancer patients. 
Keywords: Cancer stem cell, chemical compounds library, oncology screening, high-throughput screening, ovarian cancer, 
therapy resistance. 
1. INTRODUCTION 
 Epithelial ovarian carcinoma (EOC) is the sixth most 
common cancer in both European and North America  
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women and the leading cause of death from gynaecological 
malignancies [1, 2]. The lack of effective screening tests 
accounts for an advanced disease diagnosis. In addition, after 
an initial response to chemotherapy (generally a combination 
of platinum salts and taxanes), patients relapse with a 
chemo-resistant disease. Resistance to therapy has 
multifactorial causes [3]. Among them, the existence of a 
cancer stem cells (CSCs) population was put forward some 
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years ago [4, 5]. The “cancer stem cell” hypothesis states 
that tumours are hierarchically organized as their normal 
tissues counterpart, and that their long term maintenance is 
attributable to the ability of CSCs to self-renew indefinitely 
[5]. The cumulating data suggest that CSCs or cells with 
stem-like properties are much more resistant to 
chemotherapy than cells comprising the bulky tumour [6]. 
Moreover, it has been shown that transcriptional signatures 
associated to CSCs is predictive of poor overall patients 
survival, and experimental and clinical evidence suggests 
that CSCs survive to commonly used anticancer treatments 
(both cytotoxic and targeted therapy), implying that these 
cells are possibly responsible for disease recurrence and 
treatment resistance [7-9]. For these reasons the 
identification and the targeting of CSCs has been an 
important research area in oncology. 
 An unambiguous phenotype for ovarian CSC is still 
lacking, even if some hypothesis on the origin of ovarian 
cancer has been recently proposed. Indeed, recent studies 
suggest that the most high-grade serous ovarian cancer 
(~80%) originates in the ovarian fimbriae [10, 11]. 
Specifically, the hypothesis states that a stem cell in the 
fimbria could accumulate DNA damage, which may result in 
the development of a “p53 signature”, followed by 
development of a serous tubal intraepithelial carcinoma 
(STIC). These STIC lesions may shed from papillary tufts, 
and may implant on the surface of the ovary. The exposure 
to a stromal niche and autocrine signals may induce the 
development of high-grade serous carcinoma (HGSC) 
carcinogenesis and metastasis. It has been reported that the 
fimbria stem cells are characterized as c-Kit+, tubulin β4+, 
paired box 8+, and CD44+ cells, and are able to form 
spheres containing all the different fimbriae cells (ciliated, 
secretory and basally located cells) [11]. The first description 
of stem cells in ovarian cancer was reported in the ascites of 
an ovarian patient, derived from a single clone which could 
grow as spheres in culture, and could be sequentially 
propagated in tumours over several generations [12]. The 
characterization of ovarian CSCs was also studied by the 
detection of specific markers (i.e. CD133, CD117, CD24, 
and CD44), by the presence of the side population (SP, a 
particular phenotype that depends on the ability of the cells 
to extrude drugs by membrane pumps), or by the ALDH 
activity [13-16]. Alvero et al.,  were able to isolate CD44+ 
cells from primary cell lines, from tumour and ovarian 
ascites, and these could produce tumours in mice [17]. Gao 
et al reported the CD24 as a putative CSC marker in ovarian 
cancer, as few as 5,000 CD24
+
 cells were able to form 
tumours in nude mice [18]. We could isolate two ovarian 
cancer stem-like cells (#83 and #110) from fresh tumour 
samples, which were able to grow as spheres in culture [19]. 
Specifically, we demonstrated that these cells were able to 
form tumour when as few as one cell was injected in 
immune-deficient nude mice, they were able to self-renew, 
and to differentiate in vitro. We showed that these cells were 
more resistant to drugs usually used in the treatment of 
ovarian cancer (such as, cisplatin, paclitaxel), and to other 
anti-tumour drugs (such as, etoposide), than their more 
differentiated counterpart in vitro. Moreover, these spheres 
cultures present a mesenchymal phenotype, and recently 
different groups, including ours, have published that genes 
involved in epithelial-mesenchymal transition (EMT) were 
associated with overall or progression free survival, 
suggesting also contribution of EMT to the resistance 
mechanisms [19].  
 With this background, in order to find potential new 
agents in ovarian cancer, we screened the chemical library 
gathered in the frame of the COST action CM1106 
(http://www.cost.eu/COST_Actions/cmst/CM1106) on the 
survival of our two ovarian cancer cell lines (#83-SC and 
#110-SC) and in the differentiated cells derived from them 
(#83-DC and #110-DC). 
2. MATERIALS AND METHODS 
2.1. Cell Cultures 
 Low adherence cell conditions. #83 and #110 were 
grown in low adherence flasks (Corning) under stem-cell 
conditions as reported [19] serum-free DMEM/F12 medium 
supplemented with 5 µg/mL insulin (Sigma), 20 ng/mL 
human recombinant epidermal growth factor (EGF, 
Peprotech), 10 ng/mL basic fibroblastic growth factor 
(bFGF, Peprotech) and B27 Supplement (Gibco).  
2.2.1. Differentiated Cell Conditions 
 Cells from dissociated spheres were cultured in 
differentiating conditions (RPMI/F12 medium 1:1 
supplemented with 10% fetal bovine serum) for one week. 
These conditions have been demonstrated to induce cell 
differentiation [19]. After one week of culture, differentiated 
cells and those derived from dissociated spheres were plated 
in 384 well plates at a concentration of 12,500 cells/ml.  
2.2. Chemical Library 
 The chemical compound library was comprised of 576 
compounds dissolved in DMSO and stored at -20°C in pre-
prepared aliquots ready to use. It included synthetic 
compounds and natural products extracted from marine 
organisms and from plants, as well as reference compounds 
and not yet published compounds. The library is 
characterized by an extreme diversity: from glucosides, 
nucleosides to pseudo peptides.  
2.3. Drug Treatment 
 96 hours after seeding, cells were treated at the dose of 
20µM. The high-throughput screening was performed with 
an automated liquid handling system (JANUS
TM
, 
PerkinElmer), connected to a WinPREP for Janus software, 
with which it was possible to set up ad hoc programs for the 
screening (e.g. seeding and drug treatment). Cell survival 
was analyzed by the MTS assay system (Promega) 72 hrs 
after treatment. MTS reagent (5 μL) was added to each well 
and after a constant incubation time for all the plates 
absorbance was acquired using a plate reader (Infinite M200, 
TECAN). Each sample (control and treated) was done in 
triplicate. Beyond the chemical compounds included in the 
library, cells were also treated with cisplatin, as an internal 
positive control of cell toxicity in each plate. Cisplatin was 
found to be more active in differentiated cells than in stem 
cells (3% versus 25% of %Ctr), as already reported [19]. 
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2.4. Data Analysis 
 Survival data were elaborated and considered active if 
they induced a maximum of 20% cell survival compounds 
over control/untreated cells (%Ctr), calculated as: [Abs 
treated/Abs no-treated cells*100]). Positive compound 
(cisplatinum at the IC80 dose of 32µM) was included in the 
screening platform. Vehicle control was included in the 
screening (DMSO at the same concentration used in the 
screening). The t-test analysis revealed a statistical 
significance with a p value< 0.0001 for all the active 
compounds. The power of the high-throughput screening 
was evaluated by calculating the Z-score value, as previously 
described [20]. The average Z’ score for the overall 
screening was 0.69.  
3. RESULTS AND DISCUSSION 
 Under the COST Action CM1106 a library of 1200 
compounds coming from different research groups was 
assembled. The library is made up of synthetic and natural 
compounds, whose structure and mechanism of action is 
under evaluation (data not shown). We used 576 of them for 
our screening. The compounds were tested in the two 
ovarian enriched stem cell cultures #83 and #110, and in 
their differentiated counterpart. This setting has already been 
demonstrated to possibly discriminate compounds active 
(%Ctr ≤20% and 10 %) on stem cells and on the more 
differentiated counterpart [19] (Supplementary Table 1).  
 A number of compounds was found to be very active in 
both #83 and #110 cells (Fig. 1). In particular, 29 and 34 
compounds out of 576 were found to be cytotoxic (Ctr%≤ 10 
and 20%) in both SC and DC of #83 and #110 cell lines, 
respectively 4.5% and 6.0% (Fig. 1, panel A, Supplementary 
Tables 2 and 3).  Interestingly, a number of compounds were 
found to be active in both SCs (n=33) or in both DCs (n=44) 
of the #83 and #110 cell lines (Fig. 1, panel B, 
Supplementary Tables 4 and 5), suggesting the possibility to 
specifically target the former cellular subtype.  
 In addition, among the compounds contained in the 
CM1106 library, we observed that some were targeting only 
the stem-like cells (Table 1) and some only the differentiated 
cells (Table 2), while other compounds were active on both 
cell states (Table 3). The chemical structures of all the active 
compounds are reported in Fig. (2). 
 Among the most active compounds targeting stem cells, 
we found compounds with different mechanism of action. 
Sirtuins are NAD(+)-dependent class III histone deacetylases 
regulating important metabolic pathways in prokaryotes and 
eukaryotes and are involved in many biological processes, 
including cancer [21]. NJW5 is a sirtuin inhibitor whose 
discovery and validation of SIRT2 inhibitors was based on 
tenovin-6 by a ¹H-NMR method to assess deacetylase 
activity [22, 23]. We observed that compounds RN246 
(%Ctr of 17.7% and 10.3% in #83 and #110 SC, 
respectively) and RN422 (%Ctr of 4.41% and -6.2% in #83 
and #110 SC, respectively) displayed good activity, while in 
both the DCs we observed a very low cytotoxic activity. The 
syntheses of these compounds have been recently published 
[24, 25]. The more efficient compounds able to kill 90%  
 
Table 1. Compounds found to be active only in SC cells.  
# Compound #83 SC #110 SC 
Putative Mechanism 
of Action 
1 SAHA 16,00 -5,08 HDAC ihibitor 
2 NJW5 -13,65 -12,57 Sirtuin inhibitor 
3 CSA4 16, 82 6,51 Tubulin destabilizer 
4 RN 246 17,73 10,30 HDAC ihibitor 
5 RN 422 4,41 -6,17 HDAC ihibitor 
6 Sunitinib 9,80 2,61 Tyrosine kinase 
7 JK20 (R004) 14,07 6,23 Tubulin destabilizer 
8 
KO191 
(R005) 
19,53 0,45 Tubulin destabilizer 
9 BB20 -8,39 -7,08 Unknown 
10 Chaetocyne -3,25 -2,63 HMT inhibitor 
The %Ctr value for each compound is reported.  
Fig. (1). Panel A. Venn diagrams showing the number of 
compounds active in the #83 and #110 stem-like (SC) and 
differentiated cells (DC). Panel B. Number of compounds active in 
SC and DC in both #83 and #110 cell lines. The size of the circles 
are representative of the number of compounds found to be active 
in each cell population. 
 
(%Ctr≤10%) of the stem like cells were the tyrosine kinases 
inhibitors: sunitinib (platelet derived growth factor receptor- 
PDGFR, vascular endothelial growth factor receptor-
VEGFR), erlotinib (against the EGFR kinase) and dasatinib 
(against the bcrl/abl kinase), while we observed no activity 
with imatinib (against ABL, KIT, PDGFR kinases). This 
differential activity is difficult to explain and could be due to 
the different role of the kinases in the growth of SC and 
requires further work. 
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Table 2. Compounds found to be active in only DC cells. 
# Compound #83 SC #110 SC Putative Mechanism of Action 
11 PB-NODB -8,07 -7,82 HDAC inhibitor 
12 LOM 621 -4,08 -2,35 Unknown 
13 RC 960 -5,50 -2,13 HDAC inhibitor 
14 RC 714 -3,57 -4,30 HDAC inhibitor 
15 Taxol 18,03 7,15 Tubulin destablizer 
16 Camptothecin 15,06 14, 34 Topoisomerase I inhibitor 
17 BB15 14,25 15, 42 Unknown 
18 VR7 -9,50 -2,86 CDC 25 inhibitor 
19 VR10 19,51 12,86 Unknown 
20 ADTA240 -3,96 0,61 Unknown 
21 ADMR231 8,02 11,54 Unknown 
22 Entinostat 14,04 1,31 HDAC inhibitor 
23 ELTE-CSA2 15,94 10,30 Unknown 
24 MTA-BS z-1 -11,97 -3,48 Unknown 
25 MTA-BS z-3 -12,77 -10,48 Unknown 
26 MTA-BS z-4 -12,14 -8,58 Unknown 
27 ELTE-MZs-3 13,50 0,23 Unknown 
28 ELTE-MZs-8 16,29 7,26 Unknown 
29 ELTE-MZs-10 2,56 7,08 Unknown 
The %Ctr value for each compound is reported. 
 
Table 3. Compounds found to be active in both #83 and #110 SC and DC cells.  
# Compound #83 SC #83 DC #110 SC #110 DC Putative Mechanism of Action 
30 RB241 -8,53 6,99 -15,06 -0,56 Base analogue 
31 5 Aza-Cytidine 11,04 10,54 3,01 13,73 DNA demethylating agents 
32 AB-040 -7,39 -7,19 -10,06 -9,16 Base analogue 
33 Tenovin 6 -1,79 2,46 -1,00 -2,28 Sirt inhibitor 
34 PA-BU -1,20 -5,85 -5,76 -6,22 Apoptosis inducer 
35 6MeOH 15,44 -4,76 -5,44 -5,46 Apoptosis inducer 
36 RS3301 17,20 18,41 4,71 1,19 Tubulin destabilizer 
37 RS3883 19,10 17,63 10,43 15,87 Tubulin destabilizer 
38 Colchicine 15,78 17,49 6,08 3,70 Tubulin destabilizer 
39 LOM 612 -2,18 -4,08 -6,96 -2,88 Foxo inhibitor 
40 RC 173 15,79 -1,80 -1,37 1,31 Atypical retinoid 
41 Thiocolchicine 10,07 9,64 17,07 5,95 Tubulin inhibitor 
42 Podophyllotoxin 19,74 5,30 10,74 -0,42 Antimitotic 
43 LY-83-583 -10,84 -11,08 -5,22 -15,07 Guanyle cyclase inhibitor 
44 BB3 14,09 14,98 12,42 -1,08 Apoptosis inducer 
45 BB6 6,39 -9,08 -6,10 -5,51 Apoptosis inducer 
46 BB7 -10,05 -4,70 -5,63 -11,92 Unknown 
47 MIC1 -1,53 -2,88 5,03 5,25 Unknown 
48 MTA-BSz-2 7,48 -10,18 15,40 -5,13 Unknown 
49 MTA-BSz-5 6,91 -10,90 9,31 -2,03 Unknown 
50 ELTE-MZs-2 18,19 -5,63 15,35 -3,07 Unknown 
The %Ctr value for each compound is reported. 
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Fig. (2). Chemical structures of the compounds found to be active in the screening. The number under each structure refers to the number included in the 
Tables of the text. 
 
 Table 2 shows the compounds specifically active on 
differentiated cells.  Again, clinically used cytotoxic drugs 
were preferentially active on DC (taxol and camptothecin). 
Perezone (compound VR7), a CDC25 phosphatase inhibitor 
is a natural compound recently isolated from the soft coral 
Pseudopterogorgia rigida, and was found more active on 
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DC than on SC.  Phosphatases represent a group of proteins 
involved in different pathological processes, including 
cancer [26], and recent evidence suggest that their inhibition 
could have an antitumor effect [27, 28]. 
 Table 3 summarizes the compounds that were active on 
both SC and DC cells. Again, most of these compounds are 
new compounds that are under characterization. 
 The screening of this library in our experimental setting 
allowed us to find that some compound families were active 
on stem cells, while others were indistinctly active on both 
states. Apart from the cytotoxic agents and tyrosine kinases 
inhibitors, drugs modulating the gene expression have been 
clearly found to be active on both cell types. Epigenetic 
alterations through modulation of the level of acetylation and 
methylation of DNA have been shown to exert antitumor 
effect. Recently, combinations of 5-AzaC or 5-AzaDC with 
HDACi have been approved by FDA and the European 
Medicines Agency (EMA) for treatment of hematologic 
malignancies [29]. It was reported that not only the combi-
nation 5-AzaC plus butyrate targets CSCs [30], but that the 
same combination markedly reduced CSC abundance and 
increased the overall survival in a mouse model, differen-
tially regulating genes that are involved in tumor growth 
[31]. Many of the compounds we found active were epige-
netic compounds and potentially active in both stem cells 
and differentiated cells foreseeing the idea that to treat 
cancer we likely need compounds with different mechanism 
of action (epigenetic and cytotoxic), and able to kill tumor 
cells with different biological state (stem cell versus 
differentiated). 
 The fact that compounds with different specificity were 
found corroborates the notion that tumors are made up of 
different subset of cells with not only specific biological pro-
perties but also with different pharmacological sensitivities 
[32]. We found compounds active on each cell type or active 
of both. In our opinion, the most interesting are both the ones 
acting on SC, that we envisage need be used in conjunction 
with compounds active on bulky tumor cells, and the ones 
acting on both DC and SC. 
CONCLUSION 
 We successfully screened part of the chemical compound 
library (576 compounds) gathered in the frame of the COST 
action CM1106 using the recently isolated ovarian cancer 
stem cell enriched cultures and the differentiated non-
tumorigenic cells derived from them. We found compounds 
active only against cancer stem cells, only against 
differentiated cells, and compounds active against both SC 
and DC cells. From the available information, the active 
drugs belong to different chemical classes, and their 
mechanisms of action on stem cells are under study. 
 These data need to be validated in ad hoc dose-response 
cytotoxic experiments, mechanistic studies, and the 
specificity of the cytotoxic activity investigated by using a 
larger panel of cancer cell lines. Analysis of the compound 
structures is underway opening up to mechanistic drug 
studies to possibly select compounds able to improve the 
prognosis of ovarian cancer patients. 
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